eupraxia Archives - Vista Partners LLC

Eupraxia Pharmaceuticals: The Small‑Cap Biotech Quietly Seeking To Build a Billion‑Dollar Plus EoE Franchise -( $EPRX $IBB $XBI )

by Vista Partners LLC December 12, 2025 390Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX, $6.40, +1.59% today and +85.51% over the last year) is emerging as a standout small‑cap biotech, transforming a once‑niche GI indication and routine endoscopy visits into a compelling, scalable growth platform, underpinned by a mid‑teens price target from…

Eupraxia Pharma’s DiffuSphere Technology Has Shown Promising Results In Pain, Infectious Diseases, Eye Diseases And Cancers

by Vista Partners LLC January 1, 2025 71Views 0Likes

Eupraxia Pharma's (NASDAQ: EPRX) DiffuSphere technology has shown promising results in targeted drug delivery for cancer treatment. The company recently announced that its novel technology demonstrated successful targeted delivery of a chemotherapeutic agent to tumors in animal models. Key Highlights Targeted Drug…

Tag: eupraxia

Eupraxia Pharmaceuticals: The Small‑Cap Biotech Quietly Seeking To Build a Billion‑Dollar Plus EoE Franchise -( $EPRX $IBB $XBI )

Eupraxia Pharma’s DiffuSphere Technology Has Shown Promising Results In Pain, Infectious Diseases, Eye Diseases And Cancers

Your Guide To Staying Informed In The Markets